Pasireotide

Description

Product name: Pasireotide

Catalog#: 1225005

Synonyms: Growth hormone release-inhibiting factor,

CAS NO.: 108736-35-2

Sequence: Cyclo(Hyp(2-aminoethyl-carbamoyl)-Phg-D-Trp-Lys-Tyr(Bzl)-Phe)

Modifications: disulfide(2-7)

M.W: 1096.33

M.F.: C54H69N11O10S2

Purity: 95%

Counter ion: Acetate

Format: Lyophilized powder

Description: The multireceptor-targeted SRL pasireotide (Signifor®) was initially approved in 2012 by the US Food and Drug Administration (FDA) for use in patients who were considered uncontrolled after surgical treatment of a corticotroph pituitary adenoma (Cushing’s disease). Somatotroph pituitary adenomas predominantly express somatostatin receptor (SSTR) types 2 and 5. The efficacy of pasireotide in reducing GH and IGF-1 levels and in shrinking tumor in patients with acromegaly has been evaluated in Phase III clinical trials.

 

Usage: For Scientific Research Use Only, Not for Human Use.